Brak połączenia z internetem — wyświetlanie zapisanej wersji strony.

Agios Pharm

USUSD
← Do Screenera
US:AGIOLSE:0HB0

Agios Pharm (LSE:0HB0) — Biotechnology: Pharmaceutical Preparations. Liczba giełd, na których notowane są akcje spółki: 2. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.

O Firmie

Strona
agios.com
Relacje Inwestorskie
investor.agios.com/
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Siedziba
Cambridge, United States
Prezes
Brian M. Goff
Pracownicy
539
Założona
2008
Akcje w Obrocie
59.7 mln na 2026-07-24
Free Float
50.02 mln
Kapitalizacja Rynkowa
2 mld USD
Insiderzy
1.07%
Inwestorzy Instytucjonalni
112.31%
Branża (SIC)
Pharmaceutical Preparations
ISIN
US00847X1046
LEI
529900ONJHY8EOGYT555
FCF
−365 mln USD
Dług
?
Zyski i FCF — za 12 miesięcy do 30.06.2026 roku (najnowszy raport firmy).
Opis

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

reklama

Giełdy i Tickery

GiełdaTickerWalutaCenaTyp
US USA StocksAGIO główneUSD31.81 -0.34%akcje zwykłe
LSE London Stock Exchange0HB0 IOBUSD33.1105 +0.00%akcje zwykłe

Cena z 3 Miesięcy

dzień wzrostu dzień spadkuNajedź / dotknij dnia — ceny otwarcia, zamknięcia, najwyższa i najniższa

Najwięksi Akcjonariusze

PosiadaczUdziałAkcjeData Raportu
Blackrock Inc.10.81%6.46 mln2026-06-30
Farallon Capital Managem…9.91%5.92 mln2026-06-30
State Street Corporation5.92%3.53 mln2026-06-30
Lynx1 Capital Management…5.71%3.41 mln2026-06-30
Shaw D.E. & Co., Inc.5.2%3.11 mln2026-06-30
Vanguard Portfolio Manag…4.85%2.9 mln2026-06-30
Vanguard Capital Managem…4.49%2.68 mln2026-06-30
Armistice Capital, LLC4.02%2.4 mln2026-06-30
Erste Asset Management G…3.61%2.15 mln2026-06-30
SPDR SERIES TRUST-State…3.54%2.11 mln2026-08-31
Nomura Asset Management…3.54%2.11 mln2026-06-30
VANGUARD INDEX FUNDS-Van…3.16%1.89 mln2026-06-30
iShares Trust-iShares Ru…2.52%1.51 mln2026-07-31
VANGUARD INDEX FUNDS-Van…2.28%1.36 mln2026-06-30
Delaware Group Equity Fu…1.92%1.14 mln2026-05-31
VANGUARD INDEX FUNDS-Van…1.32%788 6552026-06-30
VANGUARD INDEX FUNDS-Van…1.15%683 9902026-06-30
Fidelity Salem Street Tr…1.08%646 3182026-07-31
Fidelity Rutland Square…0.88%526 1212026-07-31
iShares Trust-iShares Ru…0.86%511 9942026-07-31
FOUSE JACQUALYN A. (Dire…≈0.26%154 1562026-06-18
GHEUENS SARAH (Officer)≈0.09%54 6452026-08-04
SCADDEN DAVID T. (Direct…≈0.03%20 4192026-06-18
HO MAYKIN (Director)≈0.03%19 8482026-06-18
BALLAL RAHUL D. (Directo…≈0.03%15 2302026-06-18
SMITH CYNTHIA (Director)≈0.03%15 2302026-06-18
FOSTER-CHEEK KAYE I (Dir…≈0.02%12 4842026-06-18
ADAMS CATHERINE OWEN (Di…≈0.02%10 8652026-06-18
CAPELLO JEFFREY D (Direc…≈0.02%10 8652026-06-18
BACKSTROM JAY T (Directo…≈0%1 4472026-07-08